Nifty
Sensex
:
:
10675.40
35447.66
58.70 (0.55%)
187.12 (0.53%)

Pharmaceuticals & Drugs

Rating :
81/99

BSE: 533573 | NSE: APLLTD

564.00
-16.35 (-2.82%)
16-Nov-2018 | 12:39PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  580.35
  •  584.55
  •  563.00
  •  580.35
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  29262
  •  165.04
  •  664.00
  •  414.40

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 10,911.30
  • 21.19
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 11,529.16
  • 0.69%
  • 4.48

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 72.96%
  • 0.91%
  • 10.28%
  • FII
  • DII
  • Others
  • 0.38%
  • 5.14%
  • 10.33%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 10.94
  • -0.37

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.50
  • -9.35

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 12.30
  • -16.40

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 25.19
  • 24.26

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 7.46
  • 6.01

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 17.09
  • 14.85

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Mar 18
Mar 17
Var%
Dec 17
Dec 16
Var%
Net Sales
1,127.06
789.29
42.79%
862.53
648.19
33.07%
853.31
741.35
15.10%
840.02
777.03
8.11%
Expenses
824.72
610.14
35.17%
711.54
546.77
30.14%
680.08
606.21
12.19%
652.49
631.62
3.30%
EBITDA
302.34
179.15
68.76%
150.99
101.42
48.88%
173.23
135.14
28.19%
187.53
145.41
28.97%
EBIDTM
26.83%
22.70%
17.51%
15.65%
20.30%
18.23%
22.32%
18.71%
Other Income
2.37
7.67
-69.10%
0.10
0.17
-41.18%
0.64
0.45
42.22%
0.33
0.35
-5.71%
Interest
5.81
0.35
1,560.00%
1.57
0.89
76.40%
1.34
1.92
-30.21%
0.82
0.95
-13.68%
Depreciation
28.63
25.65
11.62%
27.60
21.84
26.37%
31.57
21.84
44.55%
26.40
21.13
24.94%
PBT
270.27
160.82
68.06%
121.92
78.86
54.60%
140.96
111.83
26.05%
160.63
123.68
29.88%
Tax
70.30
36.57
92.23%
31.54
15.48
103.75%
38.52
16.49
133.60%
29.78
39.28
-24.19%
PAT
199.97
124.24
60.95%
90.38
63.38
42.60%
102.44
95.34
7.45%
130.85
84.39
55.05%
PATM
17.74%
15.74%
10.48%
9.78%
12.01%
12.86%
15.58%
10.86%
EPS
10.61
6.45
64.50%
4.80
3.54
35.59%
4.98
4.94
0.81%
6.93
4.59
50.98%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
3,682.92
3,130.81
3,134.61
3,165.99
2,056.13
1,863.22
1,520.35
1,465.41
1,202.05
Net Sales Growth
24.60%
-0.12%
-0.99%
53.98%
10.35%
22.55%
3.75%
21.91%
 
Cost Of Goods Sold
1,017.72
886.19
887.57
823.95
639.85
627.02
609.56
637.39
534.07
Gross Profit
2,665.20
2,244.62
2,247.04
2,342.04
1,416.28
1,236.20
910.78
828.02
667.97
GP Margin
72.37%
71.69%
71.68%
73.97%
68.88%
66.35%
59.91%
56.50%
55.57%
Total Expenditure
2,868.83
2,515.55
2,519.90
2,160.88
1,660.92
1,506.16
1,271.75
1,249.54
1,059.04
Power & Fuel Cost
-
70.35
64.20
58.89
43.31
32.07
26.66
29.57
24.58
% Of Sales
-
2.25%
2.05%
1.86%
2.11%
1.72%
1.75%
2.02%
2.04%
Employee Cost
-
622.81
558.83
472.85
306.76
247.00
193.79
168.46
149.21
% Of Sales
-
19.89%
17.83%
14.94%
14.92%
13.26%
12.75%
11.50%
12.41%
Manufacturing Exp.
-
244.53
289.79
209.91
263.38
272.44
191.95
183.83
145.34
% Of Sales
-
7.81%
9.24%
6.63%
12.81%
14.62%
12.63%
12.54%
12.09%
General & Admin Exp.
-
283.43
299.79
233.28
145.68
117.73
87.73
80.25
63.01
% Of Sales
-
9.05%
9.56%
7.37%
7.09%
6.32%
5.77%
5.48%
5.24%
Selling & Distn. Exp.
-
380.23
393.14
244.62
244.69
194.03
154.78
129.93
113.65
% Of Sales
-
12.14%
12.54%
7.73%
11.90%
10.41%
10.18%
8.87%
9.45%
Miscellaneous Exp.
-
28.01
26.58
117.38
17.26
15.86
7.27
20.11
29.17
% Of Sales
-
0.89%
0.85%
3.71%
0.84%
0.85%
0.48%
1.37%
2.43%
EBITDA
814.09
615.26
614.71
1,005.11
395.21
357.06
248.60
215.87
143.01
EBITDA Margin
22.10%
19.65%
19.61%
31.75%
19.22%
19.16%
16.35%
14.73%
11.90%
Other Income
3.44
34.87
2.58
8.83
12.09
4.44
16.71
16.31
21.01
Interest
9.54
3.40
5.23
5.43
3.81
10.40
23.98
37.55
27.59
Depreciation
114.20
105.46
82.97
72.21
44.41
40.49
34.97
33.65
29.59
PBT
693.78
541.27
529.09
936.30
359.07
310.61
206.35
160.98
106.84
Tax
170.14
120.36
122.19
216.12
76.35
75.10
41.10
30.85
21.46
Tax Rate
24.52%
22.24%
23.09%
23.08%
21.26%
24.18%
19.92%
19.16%
20.09%
PAT
523.64
420.72
406.99
720.18
282.72
235.51
165.25
130.13
85.39
PAT before Minority Interest
523.46
420.91
406.90
720.18
282.72
235.51
165.25
130.13
85.39
Minority Interest
-0.18
-0.19
0.09
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
14.22%
13.44%
12.98%
22.75%
13.75%
12.64%
10.87%
8.88%
7.10%
PAT Growth
42.55%
3.37%
-43.49%
154.73%
20.05%
42.52%
26.99%
52.39%
 
Unadjusted EPS
27.32
21.89
21.39
38.19
15.01
12.49
8.77
6.90
4.53

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
2,220.14
1,902.33
1,597.36
884.64
675.57
502.94
395.00
296.73
Share Capital
37.70
37.70
37.70
37.70
37.70
37.70
37.70
11.00
Total Reserves
2,182.44
1,864.63
1,559.66
846.94
637.87
465.24
357.30
259.03
Non-Current Liabilities
597.10
94.15
84.02
72.44
94.32
103.25
122.07
150.80
Secured Loans
0.00
0.00
0.00
18.80
41.95
59.71
76.32
89.67
Unsecured Loans
500.00
0.00
0.00
0.00
10.27
10.83
18.54
38.81
Long Term Provisions
61.66
57.22
28.23
9.36
6.68
6.06
5.39
5.10
Current Liabilities
1,123.50
692.67
747.19
684.09
602.51
528.57
583.13
413.28
Trade Payables
759.32
500.73
565.65
324.94
288.44
239.96
209.15
138.57
Other Current Liabilities
142.89
81.28
51.80
44.56
60.62
69.25
151.60
84.90
Short Term Borrowings
207.78
88.51
113.71
219.70
25.42
70.11
138.43
146.28
Short Term Provisions
13.51
22.15
16.03
94.88
228.02
149.24
83.95
43.53
Total Liabilities
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81
Net Block
993.38
799.40
708.09
546.87
396.96
344.22
267.82
271.99
Gross Block
1,242.46
950.09
1,093.63
861.06
665.08
572.48
462.91
433.54
Accumulated Depreciation
249.08
150.69
385.54
314.19
268.12
228.26
195.09
161.55
Non Current Assets
2,116.31
1,316.80
917.30
750.43
515.81
415.66
364.35
308.30
Capital Work in Progress
1,010.15
396.28
92.52
83.14
20.67
32.26
58.24
26.50
Non Current Investment
41.64
49.88
53.43
2.26
3.36
3.30
3.30
3.26
Long Term Loans & Adv.
71.14
71.24
29.96
118.15
94.82
35.88
34.99
6.54
Other Non Current Assets
0.00
0.00
33.30
0.00
0.00
0.00
0.00
0.00
Current Assets
1,824.74
1,372.46
1,511.27
890.74
856.59
719.10
735.85
552.51
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
733.93
632.75
569.79
382.77
310.78
266.83
258.74
219.23
Sundry Debtors
526.34
338.82
350.48
361.17
273.37
232.87
199.33
201.97
Cash & Bank
89.92
159.60
450.83
26.83
23.96
16.11
47.09
6.29
Other Current Assets
474.55
7.56
7.09
0.00
248.48
203.29
230.68
125.02
Short Term Loans & Adv.
447.06
233.73
133.08
119.98
248.48
203.29
230.68
125.02
Net Current Assets
701.24
679.79
764.08
206.65
254.08
190.53
152.71
139.23
Total Assets
3,941.05
2,689.26
2,428.57
1,641.17
1,372.40
1,134.76
1,100.20
860.81

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
312.42
328.55
947.65
171.76
239.97
264.82
141.77
95.00
PBT
541.27
529.09
936.16
359.07
310.61
206.35
160.98
106.84
Adjustment
87.12
83.06
69.60
44.61
69.76
53.30
75.09
54.71
Changes in Working Capital
-180.85
-165.64
138.90
-162.50
-71.53
43.86
-61.59
-48.76
Cash after chg. in Working capital
447.54
446.51
1,144.66
241.18
308.84
303.51
174.48
112.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-135.12
-117.96
-197.01
-69.42
-68.87
-38.70
-32.71
-17.80
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-884.38
-485.91
-306.80
-255.61
-81.06
-67.02
-56.39
-56.82
Net Fixed Assets
-606.86
-121.60
-288.80
-200.26
-81.01
-83.59
-61.11
Net Investments
-195.85
-65.58
-4.13
0.00
-29.98
0.00
0.00
Others
-81.67
-298.73
-13.87
-55.35
29.93
16.57
4.72
Cash from Financing Activity
502.62
-128.88
-224.30
86.72
-151.06
-228.78
-44.58
-46.95
Net Cash Inflow / Outflow
-69.34
-286.24
416.55
2.86
7.86
-30.98
40.80
-8.77
Opening Cash & Equivalents
153.08
439.32
22.77
23.96
16.11
47.09
6.29
15.06
Closing Cash & Equivalent
83.74
153.08
439.32
26.83
23.96
16.11
47.09
6.29

Financial Ratios

Standalone /

Consolidated
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
117.78
100.92
84.74
46.93
35.84
26.68
20.95
49.10
ROA
12.70%
15.90%
35.39%
18.76%
18.79%
14.79%
13.27%
9.92%
ROE
20.42%
23.25%
58.03%
36.24%
39.97%
36.81%
39.14%
31.62%
ROCE
22.15%
28.87%
65.87%
37.54%
43.54%
32.05%
28.93%
21.52%
Fixed Asset Turnover
2.86
3.07
3.24
2.71
3.02
2.95
3.28
2.79
Receivable days
50.43
40.13
41.02
55.91
49.38
51.58
49.79
60.94
Inventory Days
79.67
70.01
54.91
61.11
56.34
62.73
59.30
66.15
Payable days
98.47
84.03
83.80
69.83
66.49
69.05
51.02
50.77
Cash Conversion Cycle
31.63
26.12
12.13
47.19
39.23
45.26
58.07
76.32
Total Debt/Equity
0.32
0.05
0.07
0.30
0.16
0.37
0.89
1.21
Interest Cover
160.20
102.16
173.43
95.30
30.87
9.60
5.29
4.87

Annual Reports:

News Update:


  • USFDA inspects Alembic Pharmaceuticals’ general oral solid formulation facility
    26th Oct 2018, 15:23 PM

    The facility was inspected from October 22, 2018 to October 26, 2018

    Read More
  • Alembic Pharmaceuticals reports 65% rise in Q2 consolidated net profit
    22nd Oct 2018, 14:20 PM

    Total income of the company increased by 41.72% at Rs 1,129.43 crore for Q2FY19

    Read More
  • Alembic Pharma - Quarterly Results
    22nd Oct 2018, 13:29 PM

    Read More
  • Alembic Pharmaceuticals’ JV clears first USFDA inspection at its Gujarat facility
    22nd Oct 2018, 09:06 AM

    The scheduled inspection was carried out between October 15, 2018 and October 19, 2018

    Read More
  • Alembic Pharma receives USFDA’s tentative approval for Alogliptin Tablet
    16th Oct 2018, 11:40 AM

    Alembic now has a total of 78 ANDA approvals from USFDA

    Read More
  • Alembic Pharma gets USFDA’s nod for Desvenlafaxine Extended-Release Tablets
    17th Sep 2018, 16:10 PM

    Alembic now has a total of 77 ANDA approvals (64 final approvals and 13 tentative approvals) from USFDA

    Read More
  • Alembic Pharma gets USFDA’s nod for Alogliptin, Metformin Hydrochloride Tablets
    14th Sep 2018, 11:23 AM

    Alogliptin and Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve giycemic control in adults with type 2 diabetes mellitus

    Read More
  • Alembic Pharmaceuticals to raise funds up to Rs 300 crore
    10th Sep 2018, 12:57 PM

    The Board of Directors of the company at its meeting held on September 10, 2018, approved the same

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.